Abstract
Due to the uncontrollable drug release, traditional chemotherapies could cause great side-effects and are detrimental to normal tissue or organs. Therefore, to avoid those side-effects, drug delivery system (DDS) which is capable of releasing drug molecules at target area with controllable rate according to the development of the disease or to certain functions of the organism/biological rhythm, has attracted especially focus in recent years. In this research, we devoted our efforts in constructing a core–shell nanocomposite to meet the above requirements. The superparamagnetic Fe3O4 nanoparticles were chosen as the core to introduce the magnetic guiding as well as site-specific properties in this novel drug carrier. The core was further encapsulated by silica-based molecular sieve MCM-41 (briefly denoted as MS in this research), which was consisted by immense highly ordered hexagonal tunnels to offer plenty cavity for molecules of drug. A light stimuli-responsive ligand, which is a derivative from light-responsive precursor 4,5-diazafluoren-9-one (indicated in the paper as DAFO), was further connected to the MCM-41 tunnels. The ligand can be excited by light and will flip over, making the tunnels of MCM-41 switch from close to open with light on and light off. The nanocomposite thus became capable of releasing drug molecules at certain wavelength of light. In the final, the nanoparticles were tested via SEM/TEM, XRD, FT-IR spectra, thermogravimetry and N2 adsorption/desorption to verify the structure. The MTT testing of our nanocomposite reveals no obvious cytotoxicity with non-morbid L929 murine fibroblast cells line, indicating that it could be used as a DDS candidate. The cargo releasing behaviors were studied on cytarabine loaded composite: DAFO@MS@Fe3O4 in simulated body fluids.
Similar content being viewed by others
References
Babu A, Templeton AK, Munshi A, Munshi A, Ramesh R (2013) Nanoparticle-based drug delivery for therapy of lung cancer: progress and challenges. J Nanomater 2013:14. doi:10.1155/2013/863951
Cai Y, Ling L, Li X (2015) Light-stimulated cargo release from a core–shell structured nanocomposite for site-specific delivery. J Solid State Chem 226:179–185. doi:10.1016/j.jssc.2015.02.019
Catharine JR, Scott CK, ChanMyra L, Samuels JR (1991) Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. Cancer Chemother Pharmacol 29:13–18. doi:10.1007/BF00686329
Chen Y, Mu S (2014) Core–shell structured Fe3O4 nanoparticles functionalized with rhodamine derived probe for the detection, adsorption and removal of Hg(II): a sensing system with ‘warning’ signal. Sens Actuators B Chem 192:275–282. doi:10.1016/j.snb.2013.10.135
Chhikara BS, Parang K (2010) Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion Drug Deliv 7:1399–1414. doi:10.1517/17425247.2010.527330
Delle PM, Corno M, Pedone A, Dovesi R, Ugliengo P (2014) Large-scale B3LYP simulations of ibuprofen adsorbed in MCM-41 mesoporous silica as drug delivery system. J Phys Chem C 118:26737–26749. doi:10.1021/jp507364h
DuBois SG, Krailo MD, Lessnick SL, Smith R, Chen Z, Marina N, Stegmaier K, Steven G (2009) Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 52:324–327. doi:10.1002/pbc.21822
Farzaneh F, Leila T, Mehdi G (2007) Oxidation of alkenes with molecular oxygen and isobutyraldehyde catalyzed by immobilized vitamin B12 within Al-MCM-41.”. React Kinet Catal Lett 91:333–340. doi:10.1007/s11144-007-5101-9
Gao Q, Xu Y, Wu D, Sun Y, Li X (2009) pH-responsive drug release from polymer-coated mesoporous silica spheres. J Phys Chem C 113:12753–12758. doi:10.1021/jp9043978
Gao J, Ran X, Shi C, Cheng H, Cheng T, Su Y (2013) One-step solvothermal synthesis of highly water-soluble, negatively charged superparamagnetic Fe3O4 colloidal nanocrystal clusters. Nanoscale 15:7026–7033. doi:10.1039/C3NR00931A
He QJ, Shi JL (2011) Mesoporous silica nanoparticle based nano drug delivery systems: synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J Mater Chem 21:5845–5855. doi:10.1039/C0JM03851B
Hilhorst MJ, Hendriks G, van Hout MW, Sillén H, van de Merbel NC (2011) HPLC-MS/MS method for the determination of cytarabine in human plasma. Bioanalysis 3:1603–1611
Kapoor S, Rajesh H, Aninda JB (2009) Influence of surface chemistry of mesoporous alumina with wide pore distribution on controlled drug release. J Control Release 140:34–39. doi:10.1016/j.jconrel.2009.07.015
Kruk M, Mietek J (2001) Gas adsorption characterization of ordered organic-inorganic nanocomposite materials. Chem Mater 13:3169–3183. doi:10.1021/cm0101069
Li L, Tang S, Ding D (2012) A core–shell structured nanocomposite material for detection, adsorption and removal of Hg(II) ions in water. J Nanosci Nanotechnol 12:8407–8414. doi:10.1166/jnn.2012.6668
Li WP, Liao PY, Su CH, Yeh CS (2014) Formation of oligonucleotide-gated silica shell-coated Fe3O4–Au core–shell nanotrisoctahedra for magnetically targeted and near-infrared light-responsive theranostic platform. J Am Chem Soc 28:10062–10075. doi:10.1021/ja504118q
Lin Q, Huang Q, Li C, Bao C, Liu Z, Li F, Zhu L (2010) Anticancer drug release from a mesoporous silica based nanophotocage regulated by either a one-or two-photon process. J Am Chem Soc 31:10645–10647. doi:10.1021/ja103415t
Liu J, Jiang Y, Cui Y, Xu C, Ji X, Luan Y (2014) Cytarabine-AOT catanionic vesicle-loaded biodegradable thermosensitive hydrogel as an efficient cytarabine delivery system. Int J Pharm 473:560–571. doi:10.1016/j.ijpharm.2014.07.032
Ma YC, Gao Y, Wang Y, Li Y, Yang X (2011) Synthesis and application of new ruthenium dye containing 9, 9-[di-(2-ethylhexane]-4,5-diazafluorene ligand. Modern Appl Sci 5:232. doi:10.5539/mas.v5n4p232
Phuphanich S, Maria B, Braeckman R, Chamberlain MA (2007) Pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt®) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J Neurooncol 81:2201–2208. doi:10.1007/s11060-006-9218-x
Popat A, Jambhrunkar S, Zhang J, Yang J, Zhang H, Meka A, Yu C (2014) Programmable drug release using bioresponsive mesoporous silica nanoparticles for site-specific oral drug delivery. Chem Commun 50:5547–5550. doi:10.1039/C4CC00620H
Silva EJ, Rosa TP, Herrera DR, Jacinto RC, Gomes BP, Zaia AA (2013) Evaluation of cytotoxicity and physicochemical properties of calcium silicate-based endodontic sealer MTA Fillapex. J Endod 39:274–277. doi:10.1016/j.joen.2012.06.030
Tang F, Li L, Chen D (2012) Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 24:1504–1534. doi:10.1002/adma.201104763
Wang Y, Zhao Q, Han N, Bai L, Li J, Liu J, Wang S (2015) Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomed Nanotechnol Biol Med 11:313–327. doi:10.1016/j.nano.2014.09.014
Zheng YD, Guan XC, Li D, Wang AQ, Ke CQ, Tang CP, Yao S (2016) Novel diterpenoids from the twigs of Podocarpus nagi. Molecules 21:1282. doi:10.3390/molecules21101282
Acknowledgement
The authors would like to state gratitude to our hospital and university for their financial as well as facilities support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, F., Qin, X., Xiao, D. et al. Towards site-specific nanoparticles for drug delivery application: preparation, characterization and release performance. Chem. Pap. 71, 2385–2394 (2017). https://doi.org/10.1007/s11696-017-0233-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11696-017-0233-5